Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/09/2018 07/10/2018 07/11/2018 07/12/2018 07/13/2018 Date
76.64(c) 76.75(c) 76.02(c) 77.6(c) 77.38(c) Last
8 546 543 8 380 796 6 138 750 8 956 340 4 003 769 Volume
+1.90% +0.14% -0.95% +2.08% -0.28% Change
More quotes
Financials (USD)
Sales 2018 20 799 M
EBIT 2018 10 762 M
Net income 2018 6 424 M
Debt 2018 13 028 M
Yield 2018 2,94%
Sales 2019 21 125 M
EBIT 2019 11 095 M
Net income 2019 7 133 M
Debt 2019 16 249 M
Yield 2019 3,18%
P/E ratio 2018 15,66
P/E ratio 2019 14,30
EV / Sales2018 5,46x
EV / Sales2019 5,53x
Capitalization 101 B
More Financials
Company
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need.The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey,... 
Sector
Biotechnology & Medical Research
Calendar
07/25 | 10:01pmEarnings Release
More about the company
Surperformance© ratings of Gilead Sciences
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES
07/13GILEAD SCIENCES : to Release Second Quarter 2018 Financial Results on Wednesday,..
BU
07/13GILEAD SCIENCES : Public Citizen Issues Statement on OMB Associate Director Grog..
AQ
07/12GILEAD SCIENCES : European Commission Grants Marketing Authorization for Gilead'..
AQ
07/12GILEAD SCIENCES : European CHMP Adopts Positive Opinion for Yescarta® axicabtage..
AQ
07/12GILEAD SCIENCES : New Documents Raise Concerns About Potential Conflict of Inter..
AQ
07/11GILEAD SCIENCES : Michael Amoroso to Join Kite as Senior Vice President and Head..
AQ
07/11GILEAD SCIENCES : Two pre-grant patent oppositions filed on Gileads Hepatitis C ..
AQ
07/11GILEAD SCIENCES : Planned Parenthood Announces New Phase of HIV Prevention Initi..
AQ
07/11GILEAD SCIENCES : Hepatitis c medicines face pre-grant patent oppositions
AQ
07/10GILEAD SCIENCES : Gileads senior clinical research director joins Nimbus to help..
AQ
More news
Sector news : Bio Therapeutic Drugs
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on GILEAD SCIENCES 
GILEAD SCIENCES - 2014
A valuable trading opportunity
BUY
GILEAD SCIENCES - 2014
Continuation of the bullish trend
BUY
More Strategies
Latest Tweets
03:15aJune makes a puzzling choice, and Serena Joy's illusions about Gilead are bru..
6
07/14Gilead Sciences, Inc. $GILD Short Interest Update  
07/143 Biotech Stocks With Big News Coming in NASH: After Gilead Sciences (NASDAQ:..
1
07/14Gilead Sciences to Release Second Quarter 2018 Financial Results on Wednesday.. 
07/14"Gilead steals our babies, too." I missed this pic at the London rallies toda..
33
More tweets
Qtime:405
News from SeekingAlpha
07/14STOCKS TO WATCH : Prime Time In Retail 
07/12GILEAD : Cheap Valuation For Great Pipeline 
07/12Drug prices still marching upward - Bloomberg 
07/11Big Pharma in the red after Pfizer backs away from price hikes 
07/11MONTHLY REVIEW OF DIVGRO : June 2018 
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 86,0 $
Spread / Average Target 11%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
Andrew Cheng Chief Medical Officer & Executive Vice President
John G. McHutchison Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES8.01%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.53%38 951
GENMAB5.49%10 457
NEUROCRINE BIOSCIENCES, INC.32.48%9 250
SAREPTA THERAPEUTICS INC150.58%9 136